Skip to main content
Home

Breadcrumb

  1. Home
  2. News
  3. Search results
Displaying results 626 - 650 of 673 Clear search
Zyme Communications
07 Jun 2021

MHRA confirms registration of Avacta’s AffiDX SARS-CoV-2 antigen lateral flow test

 Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the MHRA has confirmed registration of Avacta’s AffiDX® SARS-CoV-2 antigen lateral flow test, allowing the Company to place the product on the market in the UK for professional use.

Zyme Communications
07 Jun 2021

Iksuda Therapeutics closes $47 million financing round

Newcastle, UK, 07 June 2021: Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced it has completed a US $47 million (circa GB £34 million) financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners, with the Company being advised by Ashfords LLP. The funding will support…

Zyme Communications
01 Jun 2021

Japanese Patent Office upholds key Charpentier/Doudna CRISPR patent and allows third

Dublin, Ireland, 01 June 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, today announced that the Japanese Patent Office (JPO) has rejected arguments filed in opposition to the second Japanese patent (JP6692856) filed by Dr.Charpentier, together with The Regents of the University of…

Zyme Communications
20 May 2021

GammaDelta Therapeutics receives FDA Clearance of IND Application for GDX012, a novel allogeneic variable delta 1 gamma-delta T cell cancer therapy

GammaDelta Therapeutics, a company focused on exploiting the unique properties of gamma delta (γδ) T cells for immunotherapy, today announced the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the Company’s allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy, GDX012, to be investigated as a treatment for haematological…

Zyme Communications
20 May 2021

Optibrium and BioPharmics enter partnership on computational drug design

Industry-leading 3D ligand-based design approaches from BioPharmics will be available in StarDrop, Optibrium’s small molecule design and optimisation software.

Zyme Communications
18 May 2021

Charles Fracchia selected for DARPA ISAT Study Group

Boston, US, 18th May 2021: Dotmatics, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced that the US Defense Advanced Research Projects Agency (DARPA) has named Charles Fracchia, Founder of Dotmatics BioBright, to its Information Science and Technology (ISAT) Study…

Zyme Communications
12 May 2021

ERS Genomics and GenScript Biotech Corporation sign CRISPR/Cas9 licence agreement

Dublin, Ireland and Piscataway, New Jersey, 12 May 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, and GenScript Biotech Corporation (GenScript), the world’s leading research reagent provider, today announced a non-exclusive licence agreement granting GenScript access to ERS Genomics’…

Zyme Communications
12 May 2021

FUJIFILM Irvine Scientific celebrates 50 years of excellence in cell culture

FUJIFILM Irvine Scientific, Inc. is celebrating its 50th year of providing innovative cell culture media products and services. Since its formation, the Company has established a reputation as an innovator and leader in providing cell culture solutions for the Life Science and Medical markets.

Zyme Communications
11 May 2021

Hubrecht Institute licenses Flow Eighteen38 reagent antibodies for cancer research

Porto, Portugal and Utrecht, Netherlands... Flow Eighteen38 and FairJourney Biologics S.A. (FJB), leaders in the discovery and optimization of antibodies, have today announced an agreement with the Hubrecht Institute to harness the potential of FJB’s proprietary llama naïve libraries to develop antibodies to be used as research tools for the group of Hans Clevers.

Zyme Communications
06 May 2021

Bio-Rad launches its Reliance SARS-CoV-2 RT-PCR Assay Kit in Europe

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of the Reliance SARS-CoV-2 RT-PCR Kit (IVD) for European markets after having met the CE-IVD mark requirements.

Zyme Communications
05 May 2021

H.E.L Group appoints Sales Director for Asia-Pacific

H.E.L Group , a global developer and manufacturer of innovative laboratory tools for process optimization, safety, and scale-up, today announced the appointment of Oh Chee Keat (Brice Oh) as Regional Sales Director for Asia-Pacific.

Zyme Communications
28 Apr 2021

Turbine strengthens R&D capabilities with key appointments

London, UK, Budapest, Hungary... Turbine, a company developing a cell behavior simulation platform to uncover targets for the most challenging cancers, today announced that it has appointed Dr. Mark Velleca as Chair of the Board of Directors. The company also announced that Professor Gordon Mills and Dr Klaus Hoeflich have joined its Scientific Advisory Board (SAB). Drawing on their combined…

Zyme Communications
27 Apr 2021

H.E.L Group signs distribution agreement with ThalesNano Energy for H-Genie bench-top high-pressure hydrogen generator

London, UK, 27th April 2021: H.E.L Group, a global developer and manufacturer of innovative laboratory tools for process optimisation, safety and scale-up, today announced that it has signed a worldwide non-exclusive distribution agreement with ThalesNano Energy™, a developer of bench-top chemistry-focused gas generators. Covering the H-Genie® bench-top hydrogen generator and associated…

Zyme Communications
20 Apr 2021

Avacta receives clinical validation of AffiDX SARS-CoV-2 antigen lateral flow test

Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce positive data from the clinical validation of its AffiDX® SARS-CoV-2 antigen lateral flow test. Data from the clinical study conducted in Europe on 98 positive COVID-19 samples demonstrate excellent performance in…

Zyme Communications
19 Apr 2021

Adaptate Biotherapeutics raises $18 million in Series A2 funding

London, UK... Adaptate Biotherapeutics, a company focused on developing antibody-based therapeutics for modulation of gamma delta T cells, today announced that its existing investors, Abingworth and Takeda Pharmaceutical Company Limited have together made a further equity investment of $18 million (circa. £13 million).  This funding brings the total raised since Adaptate’s inception in late…

Zyme Communications
19 Apr 2021

ERS Genomics and NUVISAN ICB sign CRISPR/Cas9 licence agreement

CRISPR offerings to enhance NUVISAN’s drug development service portfolio.

Zyme Communications
13 Apr 2021

Arkema chooses Dotmatics as R&D digitalization partner

Bishop’s Stortford, UK: Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has been selected by Arkema, a global leader in speciality materials, as its informatics partner in an R&D digitalization project. Implementing Dotmatics’ unified…

Zyme Communications
12 Apr 2021

FairJourney Biologics enters next-generation antibody discovery collaboration with argenx

Porto, Portugal, and Cambridge and London, UK: FairJourney Biologics S.A (FJB) and IONTAS Limited (IONTAS), leaders in the discovery and optimisation of VHH fully human antibodies, today announced a collaboration with global immunology company, argenx to harness IONTAS’ proprietary mammalian display technology. The goal of the collaboration is to explore diverse panels of novel antibody…

Zyme Communications
07 Apr 2021

Mologic’s COVID-19 rapid antigen self-test selected by NIH for RADx initiative funding

Mologic, a leading developer of lateral flow and rapid diagnostic technologies, announced its rapid antigen self-test for COVID-19 has been selected by the Rapid Acceleration of Diagnostics (RADxSM) initiative launched by the US National Institutes of Health (NIH). The initiative aims to speed innovation in the development, commercialisation, and implementation of technologies for COVID-19…

Zyme Communications
06 Apr 2021

Avacta announces distribution agreement with Abcam plc

Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has entered into a global distribution agreement with Abcam plc (AIM: ABC; NASDAQ: ABCM) to sell the Group’s recently developed SARS-CoV-2 research ELISA Affimer® reagents.

Zyme Communications
31 Mar 2021

Dotmatics implements ‘Data to Value’ initiative with BASF Agricultural Solutions

Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced the implementation of a ‘Data to Value’ initiative with BASF’s Agricultural Solutions division.

Zyme Communications
23 Mar 2021

Insightful Science joins forces with Dotmatics to form a leading cloud-first scientific R&D company

Bishop’s Stortford, UK and San Diego, CA— Insightful Science, a leading software provider serving the global life sciences community, announced that it has entered into a transaction to acquire Dotmatics, an industry leading cloud-based scientific R&D data management platform.

Zyme Communications
22 Mar 2021

IONTAS identifies novel SARS-CoV-2 neutralising antibodies

Cambridge, UK, Porto, Portugal, and London, UK –  IONTAS Limited and FairJourney Biologics SA (FJB), leaders in the discovery and optimisation of fully human antibodies, have announced the identification of neutralising antibodies, which bind to multiple emerging SARS-CoV-2 variants.

Zyme Communications
19 Mar 2021

Aptamer Group and Mologic enter commercial partnership to develop aptamer-based SARS-CoV-2 rapid antigen test

York and Bedfordshire, UK...Aptamer Group, the developer of diagnostic and therapeuticOptimer reagents, today announced a commercial partnership with Mologic, a leading developer and manufacturer of lateral flow and rapid diagnostic tests.

Zyme Communications
17 Mar 2021

Axol Bioscience and Censo Biotechnologies announce merger

Axol Bioscience Ltd, an established provider of iPSC-derived cells, media, and characterisation services, and CENSO Biotechnologies, a cell biology CRO with focused expertise in iPSC-related technologies, today announced that the two companies have signed a merger agreement.

Pagination

  • First page «
  • Previous page ‹
  • …
  • Page 23
  • Page 24
  • Page 25
  • Current page 26
  • Page 27
  • Next page ›
  • Last page »
Receive our newsletter

Cambridge Network Limited is a company registered in England under company No. 3400152

The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

Email: [email protected], Tel: 01223 746801

© 2026 Cambridge Network. All Rights Reserved.

Website by KISS